INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
PUBLICATION OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.202210-08-2022
10-08-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of Conference Call held on August 09, 202210-08-2022
Results Earnings Call for Q1FY23 of Indoco Remedies
Conference Call with Indoco Remedies Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.09-08-2022
INDOCO REMEDIES LTD. - 532612 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation towards loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201509-08-2022
Q1FY23 Quarterly Result Announced for Indoco Remedies Ltd.
Pharmaceuticals firm Indoco Remedies announced Q1FY23 Result : During the first quarter of FY 2022-23, revenues of Indoco Remedies grew by 3.6% at Rs. 394.9 crores, as against Rs.381.2 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.1% at Rs. 71.3 crores, compared to 22.8% at Rs. 86.8 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 9.7% at Rs. 38.5 crores, compared to 10.4% at Rs. 39.6 crores, same quarter last year. Commenting on the first quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “After a turbulent India Business performance of last year with highs & lows of Covid, I am happy to report that we have a steady performance in the Domestic Business and an excellent growth in the International Business” Result PDF09-08-2022
INDOCO REMEDIES LTD. - 532612 - Results For The Quarter Ended 30Th June 2022
Results for the Quarter ended 30th June 202209-08-2022
INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Dated 09Th August, 2022
The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the Quarter ended 30th June, 2022.09-08-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of Analyst /Institutional Investors Meet03-08-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Con Call Meeting23-07-2022
INDOCO REMEDIES LTD. - 532612 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015
USFDA SUCCESSFULLY CONCLUDES INSPECTION AT ANACIPHER CRO-HYDERABAD21-07-2022